check_circleStudy Completed

Cancer

Roll-over study to continue treatment with the investigational drug rogaratinib and to further test its safety

Trial purpose

The purpose of this study is to enable patients, who are currently receiving rogaratinib in a Bayer-sponsored clinical trial (incl. NCT01976741), to continue treatment after their respective study has been closed. Another aim is to learn if rogaratinib is safe and how it affects the body.
Rogaratinib is an investigational drug that may treat different types of cancer, incl. non-small-cell lung cancer, small-cell lung cancer, urothelial carcinoma, head, neck and breast cancer. The drug may stop the growth of cancer cells by targeting different cell proteins called fibroblast growth factor receptors (FGFR) that are needed for the survival of the cancer cells.

Key Participants Requirements

Sex

All

Age

18 - N/A

Trial summary

Enrollment Goal
1
Trial Dates
October 2019 - February 2021
Phase
Phase 2
Could I Receive a placebo
No
Products
Rogaratinib (BAY1163877)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Withdrawn
Severance Hospital, Yonsei University Health SystemSeoul, 03722, Korea, Republic Of
Withdrawn
Samsung Medical CenterSeoul, 06351, Korea, Republic Of
Completed
Kantonsspital St. GallenSt. Gallen, 9007, Switzerland

Primary Outcome

  • Incidence of treatment-emergent adverse events (TEAEs)
    date_rangeTime Frame:
    Up to 55 months
  • Incidence of treatment-emergent serious adverse events (TESAEs)
    date_rangeTime Frame:
    Up to 55 months
  • Incidence of drug-related TEAEs
    date_rangeTime Frame:
    Up to 55 months
  • Incidence of drug-related TESAEs
    date_rangeTime Frame:
    Up to 55 months

Secondary Outcome

  • Frequency of dose modifications
    date_rangeTime Frame:
    Up to 55 months

Trial design

A roll-over study to provide continued treatment with rogaratinib in participants who were enrolled in rogaratinib studies
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
Single Group Assignment
Trial Arms
1